Predictive Technology Group Inc (OTCMKTS: PRED) has seen a spectacular rise over the past few years from well under $1 per share to recent highs over $5. PRED has emerged as a volume leader over the past few months as it continues to chart new 52 weeks highs.
PRED was incorporated in Nevada and was formerlly known as K-9 Concepts, Inc. until 3-2008, Aussie Soles Group, Inc. until 7-2010, The Global Housing Group. until 3-2014 and Global Enterprises Group, Inc. until 7-2015
Predictive Technology Group Inc (OTCMKTS: PRED) owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). Its novel test for women experiencing infertility, ARTGuide(TM), was launched in late 2018 to selected Beta launch centers. ARTGuide(TM) is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as IVF, are used to assist couples having difficulty conceiving a pregnancy.
The Company aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.
During the last Q CEO Bradley Robinson commented:
“I’m pleased to report our 10 consecutive quarter of sequential growth in revenue. Third quarter fiscal 2019 revenue of $11.3 million was up 167% over the third quarter of fiscal 2018. Revenue for the first nine months of fiscal 2019 exceeded $30 million, up 217% over the year-ago period, and we generated $3.1 million in cash flow from operations.
“We have made exceptional progress in building a strong infrastructure to support the development and commercialization of our proprietary genetic-based diagnostics and therapeutics,” he added. “Predictive Biotech is now operating in our recently opened, state-of-the-art production laboratory and R&D facility that was expanded to meet the production and sales needs of our human cell and tissue products for use in cellular therapies and regenerative medicine. We also finalized the integration of Taueret Laboratories and Inception Dx into Predictive Laboratories, providing us with a CAP/CLIA-accredited laboratory for processing our genetic-based tests. We strengthened our Board with the appointment of independent directors with exceptional industry, public affairs, financial and governance experience. More recently we submitted an application to list Predictive common stock for trading on the NASDAQ, a move that we believe will generate increased visibility and credibility for our Company.”
To Find out the inside Scoop on PRED Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On April 30 PRED announced it has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories. Predictive announced the acquisitions of CLIA-approved Taueret Laboratories in March 2019 and Inception Dx in September 2018. Based in Salt Lake City, Predictive Laboratories runs a state-of-the-art molecular laboratory initially focusing on human infertility and women’s health. Twenty-three skilled employees are performing high-complexity, proprietary laboratory tests. Predictive Laboratories recently purchased $6 million in new genomics equipment and supplies to expand the technical capabilities and capacities. Lab renovation will begin immediately to improve workflow efficiency. The laboratory’s new Federal CLIA number became effective today (46D1077919).
On May 2 PRED announced its submission of its application to list its common stock on NASDAQ. The Company’s management has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $1.3 billion market valuation PRED has $2.5 million in the treasury and huge sales; Revenue for the third quarter of fiscal 2019 was $11.3 million, an increase of 167% from $4.2 million for the third quarter of fiscal 2018. The increase was due to continued growth in the sales volume and increasing demand for human cell and tissue products. The Company has made exceptional progress in building a strong infrastructure to support the development and commercialization of its proprietary genetic-based diagnostics and therapeutics. PRED also finalized the integration of Taueret Laboratories and Inception Dx into Predictive Laboratories, providing them with a CAP/CLIA-accredited laboratory for processing our genetic-based tests. We will be updating on PRED when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PRED.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in PRED either long or short and we have not been compensated for this article